Introduction: Multimorbidity is highly prevalent in patients with transient ischaemic attack (TIA) or stroke, and is associated with increased short- and long-term mortality thereafter. Underlying mechanisms behind this relationship are unclear, and it is unknown whether increased inflammatory or prothrombotic factors might explain increased mortality. Methods: Using the population-based Oxford Vascular Study (OXVASC), we used a panel of 16 blood biomarkers relating to inflammation (IL-6, CRP, NGAL, sTNF-R1), thrombosis/atherogenesis (TM, fibrinogen, vWF, P-Selectin, PZ, D-Dimer, Anti-PC, ADAMTS-13), and cardiac or neuronal cell damage (NT-proBNP, hFABP, NSE, BDNF). Samples were obtained at stroke/TIA onset, and patients were followed up to 10 years. Biomarker levels were log-transformed to facilitate analysis. Multimorbidity immediately prior to TIA/stroke onset was assessed using the Charlson Comorbidity Index (CCI). Partial correlations (age-adjusted) were obtained between CCI and log-biomarker levels. Crude and adjusted hazard ratios (HRs) for all-cause mortality were obtained using Cox models, censoring at 2, 5, and 10 years. Results: 1297 participants (median age 75.2, interquartile range: 65.3 - 83.2) were recruited from 2002-2012. 596 patients (46.0%) had no CCI comorbidity, 266 (20.5%) had 1, and 435 (33.5%) had 2 or more. After adjustment for age, CCI was correlated with IL-6, NGAL, sTNF-R1, TM, fibrinogen, vWF, D-Dimer, NT-proBNP, and hFABP (all p <0.05). CCI was associated with all-cause death at 10 years follow up (HR 1.51, 95%CI 1.38 - 1.64). This association remained significant after adjustment for age, sex, and stroke severity (HR 1.37, 95%CI 1.26 - 1.49) and after further adjustment for inflammatory markers (HR 1.43, 95%CI 1.26 - 1.62), thrombotic/antiatherogenic markers (HR 1.37, 95%CI 1.20 - 1.56), or markers of cardiac or neuronal cell damage (HR 1.33, 95%CI 1.21 - 1.47). Censoring at 2 or 5 years follow-up provided similar estimates. Conclusion: Multimorbidity was predictive of all-cause mortality after TIA/stroke, but the association was not explained by our panel of biomarkers. Further work is needed to explain the excess risk of mortality associated with multimorbidity in stroke/TIA patients.
Read full abstract